Merck (@Merck)
@Merck
0 正在关注 0 粉丝
In collaboration with @moderna_tx, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely resected stage IIB-IV #melanoma#:
显示更多
Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries.
Learn more:
显示更多
An antibody-drug conjugate (ADC) is a complex molecule designed to target and destroy cancer cells through the transport and delivery of chemotherapy.
Our business development and licensing team looks for opportunities to complement and augment our pipeline where science and value align.
Our One Pipeline strategy enables us to advance bold science, whether it comes from our own labs or from our collaborator’s labs.
With our broad set of global resources, we work alongside our partners to move bold science forward.
Our One Pipeline strategy enables us to advance bold science, whether it comes from our own labs or from our collaborator’s labs.
We believe great medicines start with great conversations.
Our research is helping us lead the next wave of cancer care and strive for a future where cancer is not just treated but cured.
We follow the science that helps impact lives. See how we're helping lead the next wave in cancer care.
